Details

Autor(en) / Beteiligte

• Weimer, Liliana Elena
• Fragola, Vincenzo
• Floridia, Marco
• Guaraldi, Giovanni
• Ladisa, Nicoletta
• Francisci, Daniela
• Bellagamba, Rita
• Degli Antoni, Anna
• Parruti, Giustino
• Giacometti, Andrea
• Manconi, Paolo Emilio
• Vivarelli, Angela
• D'Ettorre, Gabriella
• Mura, Maria Stella
• Cicalini, Stefania
• Preziosi, Roberta
• Sighinolfi, Laura
• Verucchi, Gabriella
• Libertone, Raffaella
• Tavio, Marcello
• Sarmati, Loredana
• Bucciardini, Raffaella

Titel

Response to raltegravir-based salvage therapy in HIV-infected patients with hepatitis C virus or hepatitis B virus coinfection

Ist Teil von

• Journal of antimicrobial chemotherapy, 2013-01, Vol.68 (1), p.193-199

Ort / Verlag

England: Oxford Publishing Limited (England)

Erscheinungsjahr

2013

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• To define the impact of coinfection with hepatitis B virus (HBV) or hepatitis C virus (HCV) on viroimmunological response to raltegravir-based salvage regimens that also include new HIV inhibitors such as maraviroc, darunavir and etravirine. We used data from a national observational study of patients starting raltegravir-based regimens to compare virological suppression and CD4 cell change from baseline in patients with and without concomitant HBV or HCV infection. Overall, 275 patients (107 coinfected and 168 non-coinfected) were evaluated. Coinfected patients were more commonly former intravenous drug users and had a longer history of HIV infection and higher baseline aminotransferase levels. Both HIV-RNA and CD4 response were similar in the two groups. Mean time to first HIV-RNA copy number <50 copies/mL was 4.1 months (95% CI 3.5-4.6) in non-coinfected patients and 3.9 months (95% CI 3.3-4.5) in coinfected patients (hazard ratio 1.039, 95% CI 0.761-1.418, P = 0.766, log-rank test). The risk of developing new grade 3-4 hepatic adverse events was significantly higher in coinfected patients (hazard ratio 1.779, 95% CI 1.123-2.817, P = 0.009). The two groups of coinfected and non-coinfected patients had similar rates of interruption of any baseline drug (hazard ratio 1.075, 95% CI 0.649-1.781, P = 0.776) and of raltegravir (hazard ratio 1.520, 95% CI 0.671-3.447, P = 0.311). Few AIDS-defining events and deaths occurred. Viroimmunological response to regimens based on raltegravir and other recent anti-HIV inhibitors is not negatively affected by coinfection with HBV or HCV. Liver toxicity, either pre-existing or new, is more common in coinfected patients, but with no increased risk of treatment interruption.